financetom
Business
financetom
/
Business
/
Market Chatter: OpenAI Seeks to Cut Microsoft's Revenue Share in Restructuring Talks
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: OpenAI Seeks to Cut Microsoft's Revenue Share in Restructuring Talks
May 26, 2025 3:03 AM

03:37 PM EDT, 05/07/2025 (MT Newswires) -- Microsoft ( MSFT )-backed (MSFT) OpenAI, which is proceeding with a corporate restructuring that requires Microsoft's ( MSFT ) approval, is looking to cut the share of revenue it gives to the tech giant as part of the desired plan, The Information reported late Tuesday, citing people with knowledge of the matter.

OpenAI's current deal reportedly requires it to share 20% of its revenue with Microsoft ( MSFT ) until 2030, when it expects to generate revenue of $174 billion. The AI company now wants to cut that to 10% by 2030, although it may rise to 28% in the next few years, the report said.

Some OpenAI leaders want Microsoft ( MSFT ) to let future OpenAI products bypass the current revenue-sharing agreement, according to the report.

The two companies are still discussing how much ownership Microsoft ( MSFT ) will have in OpenAI's for-profit division, as Microsoft ( MSFT ) also wants long-term rights to use OpenAI's technology as part of the deal, the report said.

Talks are ongoing about how OpenAI will continue using Microsoft's ( MSFT ) Azure cloud services as part of the deal, one of the people said.

Microsoft ( MSFT ) and OpenAI did not immediately respond to requests for a comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 435.03, Change: +1.72, Percent Change: +0.40

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Redwire Plans to Appoint Chris Edmunds as Chief Financial Officer
Redwire Plans to Appoint Chris Edmunds as Chief Financial Officer
Oct 7, 2025
08:17 AM EDT, 10/07/2025 (MT Newswires) -- Redwire ( RDW ) said Tuesday it intends to appoint Chris Edmunds as chief financial officer, replacing Jonathan Baliff, who will retire, effective Nov. 30. Edmunds currently serves as the company's chief accounting officer. Baliff will serve as a consultant through December 2026, Redwire ( RDW ) said. The company's shares were up...
Dye & Durham to Sell UK Unit Credas Technologies to SmartSearch for 77.8 Million Pounds
Dye & Durham to Sell UK Unit Credas Technologies to SmartSearch for 77.8 Million Pounds
Oct 7, 2025
08:18 AM EDT, 10/07/2025 (MT Newswires) -- Dye & Durham Limited ( DYNDF ) , a provider of cloud-based legal practice management software trading near 52 week lows, said Tuesday that it entered into a definitive agreement to sell Credas Technologies, a UK-based provider of identity verification and anti-money laundering solutions, to SmartSearch, an established UK provider of anti-money laundering...
Telomir Says Investigational Therapy Reactivates Tumor Suppressor Genes in Preclinical Models
Telomir Says Investigational Therapy Reactivates Tumor Suppressor Genes in Preclinical Models
Oct 7, 2025
08:17 AM EDT, 10/07/2025 (MT Newswires) -- Telomir Pharmaceuticals ( TELO ) said Tuesday that preclinical results show that its investigational therapy Telomir-1 reactivated two tumor suppressor genes, potentially preventing the spread of cancer and improving responses to chemotherapy. The results showed that the experimental therapy reactivated the MASPIN and RASSF1A genes through DNA methylation reset in prostate cancer models,...
Fractyl Health Says Obesity Drug Candidate Shows Weight Loss in Preclinical Trial
Fractyl Health Says Obesity Drug Candidate Shows Weight Loss in Preclinical Trial
Oct 7, 2025
08:17 AM EDT, 10/07/2025 (MT Newswires) -- Fractyl Health ( GUTS ) said Tuesday that new preclinical data from its obesity candidate RJVA-002 showed 30% weight loss in mice after a single dose, with no adverse effects observed. The company said the study used a diet-induced obesity model with humanized GIP receptors and demonstrated a dose-dependent reduction in body weight...
Copyright 2023-2026 - www.financetom.com All Rights Reserved